BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $IPN.PA readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07427797-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:LAURITE 1 readout (P3) · Ipsen $IPN.PA
DESCRIPTION:A Study to Assess the Effectiveness and Safety of IPN10200 in A
 dults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows\n\nP
 rimary completion date: 2026-12-15 (estimated)\nPhase 3 · Other · Modera
 te to Severe Glabellar Lines\nEnrollment: 309 · Sites: 23\n\nPrimary comp
 letion = last participant's primary-endpoint data collected\; topline resu
 lts usually follow weeks to months later. Sponsor-reported\, often an esti
 mate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT0
 7427797\nhttps://clinicaltrials.gov/study/NCT07427797
URL:https://datacutoff.com/radar.html?nct=NCT07427797
CATEGORIES:Other,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07435428-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:LAURITE 2 readout (P3) · Ipsen $IPN.PA
DESCRIPTION:A Study to Assess the Effectiveness and Safety of IPN10200 Over
  Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eye
 brows\n\nPrimary completion date: 2026-12-15 (estimated)\nPhase 3 · Other
  · Moderate to Severe Glabellar Lines\nEnrollment: 1300 · Sites: 60\n\nP
 rimary completion = last participant's primary-endpoint data collected\; t
 opline results usually follow weeks to months later. Sponsor-reported\, of
 ten an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.ht
 ml?nct=NCT07435428\nhttps://clinicaltrials.gov/study/NCT07435428
URL:https://datacutoff.com/radar.html?nct=NCT07435428
CATEGORIES:Other,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06730061-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:ELONSEN readout (P3) · Ipsen $IPN.PA
DESCRIPTION:A Study of Elafibranor in Adult Japanese Participants With Prim
 ary Biliary Cholangitis (PBC)\n\nPrimary completion date: 2026-12-17 (esti
 mated)\nOriginally planned: 2026-03-19 (+9.0 months)\nPhase 3 · GI·Renal
 ·Heme · Primary Biliary Cholangitis\nEnrollment: 18 · Sites: 16\n\nPrim
 ary completion = last participant's primary-endpoint data collected\; topl
 ine results usually follow weeks to months later. Sponsor-reported\, often
  an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?
 nct=NCT06730061\nhttps://clinicaltrials.gov/study/NCT06730061
URL:https://datacutoff.com/radar.html?nct=NCT06730061
CATEGORIES:GI·Renal·Heme,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06937931-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270326
DTEND;VALUE=DATE:20270327
SUMMARY:CATALPA readout (P2) · Ipsen $IPN.PA
DESCRIPTION:A Study of IPN10200 for the Treatment of Cervical Dystonia in A
 dults\n\nPrimary completion date: 2027-03-26 (estimated)\nOriginally plann
 ed: 2026-02 (+13.7 months)\nPhase 2 · Other · Cervical Dystonia\nEnrollm
 ent: 132 · Sites: 45\n\nPrimary completion = last participant's primary-e
 ndpoint data collected\; topline results usually follow weeks to months la
 ter. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps
 ://datacutoff.com/radar.html?nct=NCT06937931\nhttps://clinicaltrials.gov/s
 tudy/NCT06937931
URL:https://datacutoff.com/radar.html?nct=NCT06937931
CATEGORIES:Other,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06625060-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:MERANTI readout (P2) · Ipsen $IPN.PA
DESCRIPTION:A Study to Evaluate IPN10200 Safety and Efficacy in the Prevent
 ion of Episodic or Chronic Migraine in Adults\n\nPrimary completion date: 
 2027-10-31 (estimated)\nOriginally planned: 2027-05-31 (+5.0 months)\nPhas
 e 2 · Neuro · Episodic Migraine\, Chronic Migraine\nEnrollment: 670 · S
 ites: 162\n\nPrimary completion = last participant's primary-endpoint data
  collected\; topline results usually follow weeks to months later. Sponsor
 -reported\, often an estimate. Not investment advice.\n\nhttps://datacutof
 f.com/radar.html?nct=NCT06625060\nhttps://clinicaltrials.gov/study/NCT0662
 5060
URL:https://datacutoff.com/radar.html?nct=NCT06625060
CATEGORIES:Neuro,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
